Program - Dr. Falk / Falk Foundation

Falk Workshop
Viral Hepatitis –
From Bench to Bedside
January 29 – 30, 2015
Klinikum rechts der Isar
Munich, Germany
Program
Awarded
with
6
CME credits
1
2
Preface . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4
Scientific Program . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
6
Posters . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
8
List of Speakers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
12
Information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
6 credit hours (CME) have been awarded for the Falk Workshop by the European Union
of Medical Specialists (UEMS) - European Board of Gastroenterology (EBG).
3
Preface
Dear Colleagues,
It is a great pleasure to welcome you in Munich to the Falk workshop “Viral Hepatitis –
From Bench to Beside“ in association with the 31st Annual Meeting of the German
Association for the Study of the Liver.
The scientific organizers of this year’s workshop are excited to offer young clinicians,
clinical experts and scientists of interdisciplinary backgrounds the opportunity of scientific
exchange related to viral hepatitis, the most common cause of liver disease worldwide.
We are proud to have put together a strong curriculum of leading researchers of both
national and international renown that reflects the mission of the Falk Foundation to
improve patient outcomes through innovation and education.
We are looking forward to discussing recent advances and major challenges in the
discovery and validation of new therapeutic targets and antivirals, the understanding of
molecular and cellular pathways in the development of chronicity, the identification of
immunological signatures of chronic infections and the crosstalk between innate and
adaptive immune responses. In addition, we look forward to hearing from international
experts in the field how basic findings can be translated into the development of novel
therapies and vaccines for the clinics to fight HBV, HCV and HDV. Perhaps even most
importantly, we hope to provide you with a stimulating environment that provides the
basis for promising collaborations and the development of new therapeutic approaches
in order to – as stated in the title of this workshop – succeed in a bench-to-bedside
translation.
We would like to thank all speakers, chairpersons and workshop participants for taking
time out of your busy schedules in order to actively participate in this successful event.
We would also like to thank the Falk Foundation for this excellent opportunity of scientific
exchange. We wish you an exciting and productive workshop as well as an enjoyable stay
in Munich.
Sincerely,
Ulrike Protzer, Norbert Grüner, Roland Schmid
4
Falk Workshop
Viral Hepatitis –
From Bench to Bedside
January 29 – 30, 2015
Klinikum rechts der Isar
Munich, Germany
The 31th Annual Meeting of the
German Association for the
Study of the Liver will follow
the Falk Workshop:
January 30, 13.30 h to
January 31, 12.30 h
Information:
Prof. Dr. Ulrike Protzer
Virologie
Technische Universität München
Trogerstr. 30
81675 München
Germany
Telephone: +49 (0)89/4140-6821
Telefax:
+49 (0)89/4140-6823
E-Mail:[email protected]
Official Language:
English
Scientific Organization:
U. Protzer, Munich (Germany)
N. H. Grüner, Munich (Germany)
R. M. Schmid, Munich (Germany)
Congress Venue:
Klinikum rechts der Isar
Pavillon / Hörsaal B
Ismaninger Str. 22
81675 Munich
Germany
Posters:
For details see page 8
5
Thursday, January 29, 2015
(Lecture Hall: Pavillon)
12.30 Welcome lunch and poster session
13.30 Welcome
U. Protzer,
Munich
ession
S
I
Molecular virology defines new therapeutic targets
Chair: D. Durantel, Lyon; T. Pietschmann, Hannover
13.35 Non-cytolytic degradation of HBV cccDNA
J. Lucifora,
Lyon
14.05 Hepatitis C virus entry inhibition
T. F. Baumert,
Strasbourg
14.35 Molecular targets of antiviral therapy for hepatitis C
R. Bartenschlager,
Heidelberg
15.05 HCV mouse models in antiviral and vaccine development
A. Ploss,
Princeton
15.35 Coffee break with poster session
ession
S
II
Immunological determinants of persistence
and clearance
Chair: J. Nattermann, Bonn; R. Thimme, Freiburg
16.00 Contrasting innate immune response to hepatitis A
and hepatitis C viruses, positive-strand hepatitis viruses
with divergent infection outcomes
S. M. Lemon,
Chapel Hill
16.30 Cellular immune responses
B. Rehermann,
Bethesda
17.00 Viral and host contributions to the outcome of hepatitis
virus infection S. Wieland,
La Jolla
17.30 Innate regulation of T cell responses
M. Maini,
London
6
Friday, January 30, 2015
(Lecture Hall: Hörsaal B)
S
ession III
Bringing novel therapies into the clinics: HBV
Chair: T. Berg, Leipzig; M. Dandri, Hamburg
9.00 Entry inhibition of hepatitis B and D virus: from basic in vitro findings to novel therapies S. Urban,
Heidelberg
9.30 Cellular therapies for HBV
A. Bertoletti,
Singapur
10.00 Therapeutic vaccines in treating chronic hepatitis B:
from bench to bedside and back
M.-L. Michel,
Paris
10.30 Coffee break and poster session
S
ession
IV
Bringing novel therapies and vaccines
into the clinics: HCV
Chair: G. Gerken, Essen; M. P. Manns, Hannover
11.00 Vector based vaccines in clinical trials
E. Barnes,
Oxford
11.30 Optimisation of a recombinant gpE1/gpE2 vaccine
component for future clinical trials
J. Law,
Edmonton
12.00 Antiviral therapies for chronic hepatitis C
S. Zeuzem,
Frankfurt
12.30Farewell
12.40 Farewell lunch
13.30 Opening of the Annual Meeting of the GASL
7
Poster Session
Posters will be exhibited on January 29–30, 2015, at Klinikum rechts der Isar in
Munich (Germany). The authors will be in attendance during coffee and lunch breaks
on both days.
1.Diagnostic discrepancy for hepatitis C virus infection in haemodialysis patients in
Bulgaria
M.V. Atanasova, R. Komitova, T. Argirova, M. Nyagolovg, A. Ivanova (Plovdiv,
Sofia, BG)
2.The disease course of chronic HBV infection among pediatric patients
O.-A. Belei, M. Pop, L. Olariu, I. Simedrea, O. Gradinaru-Tascau, O. Marginean
(Timisoara, RO)
3.Bispecific antibody constructs mediate immunotherapeutic retargeting of effector
cells towards HBV infected target cells
F. Bohne, J. Hasreiter, O. Quitt, V. Bruss, G. Moldenhauer, F. Momburg, U. Protzer
(Munich, Neuherberg, Heidelberg, DE)
4.Viral replication in HBV transgenic mice lacking the surface antigen is accompanied
by Toll-like receptor 3-mediated antiviral responses
R. Bröring, C. Real, M. Lu, M. Hossbach, J. Deckert, K. Jahn-Hoffmann,
L.M. Ickenstein, M.J. John, K. Gibbert, U. Dittmer, H.-P. Vornlocher, R. Schirmbeck,
G. Gerken, J.F. Schlaak (Essen, Kulmbach, Frankfurt, Biberach a. d. Riss, DE;
Cambridge, US; Ulm, Duisburg, DE)
5.HBsAg-specific humoral and cellular immune memory after hepatitis B booster
vaccination in adolescents 10–15 years after immunization in infancy
I. Brunskole Hummel, A. Zitzmann, J.J. Wenzel, W. Jilg (Regensburg, DE)
6.Performance of the aspartate aminotransferase-to-platelet ratio index for
predicting advanced liver fibrosis in chronic hepatitis C Tunisian patients
M. Cheikh, H. Romdhane, R. Ennaifer, W. Bougassas, H. Ben Nejma, N. Bel Hadj
(Tunis, TN)
7.Interest of liver biopsy in chronic hepatitis B patients with ALT ≥ 2N and HBV DNA
≥ 20,000 IU/ml. Results of a Tunisian survey
M. Cheikh, R. Ennaifer, H. Romdhane, N. Elleuch, H. Ben Nejma, W. Bougassas,
N. Bel Hadj (Tunis, TN)
8.Delta like ligand 4 ameliorates liver fibrogenesis through inhibition of inflammatory
chemokines
B. Dewidar, Y. Liu, Z. Shen, J. Hu, T. Feng, O. Park, H.G. Augustin, B. Gao, Y.-M. Li,
S. Dooley, H.-L. Weng (Mannheim, DE; Hangzhou, CN; Heidelberg, DE; Maryland,
US)
8
9.Submassive hepatic necrosis distinguishes HBV-associated acute-on-chronic liver
failure from cirrhotic patients with acute decompensation
S. Dooley, Q. Xia, S.-T. Li, T.-L. Wang, H.-L. Weng, H. Li (Mannheim, DE; Shanghai,
Beijing, CN)
10.Genotypic and phenotypic analysis in hepatitis C virus infected patients, the
continuous need for resistance testing
H. Gaber, D. Rupp, C. Bach, K. Zhang, C. Yazici, D. Hoffman, R. Bartenschlager,
U. Protzer (Munich, Heidelberg, DE)
11.The predictive factors in the response to antiviral therapy in chronic hepatitis C
A. Gaman, A. Ungureanu, C. Georgescu, C. Vasile, M. Dobritoiu, E.F. Georgescu
(Craiova, RO)
12.Efficiency of treatment with peginterferon alfa-2a in patients with Ag HBe positive
chronic liver disease
O. Gradinaru-Tascau, M. Popescu, O. Belei (Timisoara, RO)
13.Loss of HBsAg-expression ameliorates liver serum parameters and reduces ERstress in HBV-transgenic mice
F. Graumann, Y. Churin, M. Roderfeld, D. Schröder, D. Glebe, E. Roeb (Giessen,
DE)
14.Sperm protein 17 and AKAP-associated sperm protein cancer-testis antigens are
expressed in ciliated hepatic foregut cysts
F. Grizzi, B. Franceschini, S. Di Biccari, S. Musardo, M. Chiriva-Internati, V. Osipov,
M.J. Fernandez-Acenero (Rozzano, Milan, IT; Lubbock, Milwaukee, US; Madrid, ES)
15.Identification of a new TCAB1 mutation in hepatitis C-induced liver cirrhosis
D. Hartmann, D. Klein, G. von Figura, H. Friess, G.O. Ceyhan (Munich, DE)
16.Screening for hepatitis B in inflammatory bowel disease patients: Are recommendations already applied?
L. Kallel, M. Mahmoudi, R. Ben Jemaa, M. Hafi, N. Ben Mustapha, M. Serghini,
M. Fekih, J. Boubaker, A. Filali (Tunis, TN)
17.H. pylori eradication (sequential) therapy influence on motor function of the
stomach in patients with overlap-syndrome, functional dyspepsia combined with
non-erosive reflux disease
N. Kharchenko, I. Korulya, D. Janelidze (Kiev, UA)
18.The relationship between acid gastoesophageal reflux and depression level in Hp
negative patients with overlap-syndrome (functional dyspepsia/non-erosive reflux
disease)
N. Kharchenko, I. Lopukh, D. Janelidze (Kiev, UA)
19.A diagnostic algorithm of overlap-syndrome‘s (functional dysepsia/non-erosive
reflux disease) different variants
N. Kharchenko, V. Kharchenko, D. Janelidze (Kiev, UA)
9
20.The interaction of hepatitis B virus infection and schistosomiasis in chronic
pathogen-induced liver inflammation
E. Loffredo-Verde, U. Protzer, C. Prazeres da Costa, D.H. Busch (Munich, DE)
21.Non invasive serum fibrosis markers in comparison with grading and staging in
chronic hepatitis B
M. Mahmoudi, N. Ben Mustapha, R. Ben Jemaa, M. Serghini, L. Kallel, M. Fekih,
S. Matri, J. Boubaker, A. Filali (Tunis, TN)
22.Previous interferon therapy does not lead to a better virological response in
patients treated with entecavir
M. Mahmoudi, F. Houissa, S. Ayedi, K. El Jeri, S. Bouzaidi, Y. Said, L. Mouelhi,
S. Khedher, H. Mekki, M. Salem, R. Debbeche, T. Najjar (Tunis, TN)
23.The inactive HBV-carrier profile: the long-term outcome
M. Mahmoudi, N. Ben Mustapha, R. Ben Jemaa, M. Serghini, L. Kallel, M. Fekih,
S. Matri, J. Boubaker, A. Filali (Tunis, TN)
24.Substained virological response is low in diabetic Tunisian chronic hepatitis C
patients
M. Mahmoudi, K. El Jeri, S. Ayedi, S. Bouzaidi, L. Mouelhi, F. Houissa, Y. Said,
H. Mekki, S. Khedher, M. Salem, T. Najjar (Tunis, TN)
25.The anti-TNF-α antibody infliximab inhibits the expression of fat-transporter-protein
FAT/CD36 in a selective hepatic-radiation mouse model
I. Malik, M. Rave-Fränk, H. Wolff, G. Martius (Göttingen, DE)
26.Peroxisome proliferator activated receptor gamma agonists are less effective in
chronic hepatitis C (CHC) compared to nonalcoholic steatohepatitis (NASH)
O. Plehutsa, L.P. Sydorchuk, AR. Sydorchuk, I. Sydorchuk, R.I. Sydorchuk
(Chernivtsi, UA)
27.Transcriptional phenotype of virus-specific CD4+ and CD8+ T-cells during acuteresolving and chronic hepatitis B virus infection
B. Raziorrouh, P. Kurktschiev, W. Schraut, R. Zachoval, M. Wächtler, M. Spannagl,
H. Diepolder, M.-C. Jung, N.H. Grüner (Munich, Kaufbeuren, DE)
28.Specific and non-hepatotoxic degradation of nuclear hepatitis B virus cccDNA by
lymphotoxin-beta receptor activation
F. Reisinger, J. Lucifora, E. Dejardin, Y. Xia, K. Zhang, D. Stadler, X. Cheng,
W.-M. Chou, J. Browning, C. Münk, M. Landthaler, U. Protzer, M. Heikenwälder
(Munich, DE; Lyon, FR; Liège, BE; Cambridge, US; Düsseldorf, Berlin, DE)
29.Targeting active demethylation; a new possible mechanism in treatment of
hepatocellular carcinoma
S.O. Sajadian, S. Ehnert, A. Bachmann, B. Sipos, A.K. Nüssler (Tübingen, DE)
30.Hepatoprotective role of Nerium oleander in thioacetamide induced chronic
inflammation
N. Sheikh, T. Akhtar (Lahore, PK)
10
31.A simple and rapid plate-based LC-MS/MS assay for the analysis of serum
25-hydroxyvitamin D levels in patients with chronic liver disease
C. Stokes, T. Geib, F. Meier, P. Schorr, F. Lammert, D. Volmer
(Homburg, Saarbrücken, DE)
32.Is systemic inflammation, liver cirrhosis and cancerogenesis in chronic hepatitis C
patients associated with T894G polymorphism of endothelial nitric oxide synthase
gene and vascular injury?
A.R. Sydorchuk, L.P. Sydorchuk, R.I. Sydorchuk, I. Sydorchuk (Chernivtsi, UA)
33.Therapeutic (pro-metabolic) influence on peroxisome proliferator activated
receptor gamma in chronic hepatitis C (CHC) and nonalcoholic steatohepatitis
(NASH) patients is determined by PPAR-G Pro12Ala gene polymorphism
L.P. Sydorchuk, A.R. Sydorchuk, I. Sydorchuk, O. Plehutsa, R.I Sydorchuk
(Chernivtsi, UA)
34.HCV infection and relationship between gut microflora, antiendotoxin core
antibodies and nitric oxide levels
R.I. Sydorchuk, L.P. Sydorchuk, O. Plehutsa, I. Sydorchuk, A. Sydorchuk
(Chernivtsi, UA)
35.Myrcludex-B inhibits hepatitis delta superinfection and spreading in HBV stably
infected humanized mice
T. Volz, K. Giersch, L. Allweiss, O.D. Bhadra, J. Petersen, A.W. Lohse, S. Urban,
M. Lütgehetmann, M. Dandri (Hamburg, Heidelberg, DE)
36.HCV-therapy reduced not only the liver-related, but overall morality too – results in
the Leipzig anti-D cohort
M. Wiese (Leipzig, DE)
37.Increased hepatic expression level of novel microRNA in ABCB4-/- mice
T. Würger, Y. Churin, M. Roderfeld, E. Roeb (Giessen, DE)
11
List of Speakers, Moderators and Scientific Organizers
Dr. Eleanor Barnes
Peter Medawar Building for Pathogen
Research
University of Oxford
South Parks Road, Oxford OX1 3SY
Great Britain
[email protected]
Prof. Dr. Ralf Bartenschlager
Universität Heidelberg
Im Neuenheimer Feld 345
69120 Heidelberg
Germany
[email protected]
Prof. Dr. Thomas Baumert
INSERM, U1110
Institute for Viral and
Liver Diseases
University of Strasbourg
3 Rue Koeberlé
67000 Strasbourg
France
[email protected]
Prof. Dr. Thomas Berg
Gastroenterologie/Rheumatologie
Universitätsklinikum Leipzig AöR
Liebigstraße 20
04103 Leipzig
Germany
[email protected]
Dr. Antonio Bertoletti
Duke-Nus Medical School
Emerging Infectious Diseases Pro
8 College Road
Singapur 169857
Singapore
[email protected]
Prof. Dr. Maura Dandri
Medizinische Klinik I
Universitätsklinikum Hamburg-Eppendorf
Martinistr. 52
20246 Hamburg
Hamburg
Germany
[email protected]
12
Dr. David Durantel
INSERM, U1052
Cancer Research Center
University of Lyon
151 cours Albert Thomas
Lyon
France
[email protected]
Prof. Dr. Guido Gerken
Gastroenterologie/Hepatologie
Universitätsklinikum Essen
Hufelandstr. 55
45147 Essen
Germany
[email protected]
PD Dr. Norbert H. Grüner
Medizinische Klinik II
Klinikum der Universität
München - Großhadern
Marchioninistr. 15
81377 München
Germany
[email protected]
Dr. John Law
Dept. of Medical Microbiology
and Immunology
Li Ka Shing Virology Institute
University of Alberta
Katz Group Cent Room No. 6-096
T6G 2E1 Edmonton, AB
Canada
[email protected]
Stanley M. Lemon, M.D.
Professor of Medicine and
Microbiology & Immunology
8.034 Burnett-Womack Clinical
Sciences Bldg.
Manning Drive CB# 7292
University of North Carolina
Chapel Hill, NC 27599-7292
USA
[email protected]
Dr. Julie Lucifora
Centre de Recherche en Cancérologie de
Lyon (CRCL)
INSERM 1052 - UMR CNRS 5286
Département Immunité, Virus et
Microenvironnement
Equipe 15 „Pathogénèse de l‘hépatite B et C“
151 Cours Albert Thomas
69424 Lyon Cedex 03
France
[email protected]
Prof. Dr. Mala Maini
Division of Infection and
Immunity UCL
Rayne Institute
5 University Street
London
WC1E 6JF
Great Britain
[email protected]
Prof. Dr. Michael P. Manns
Klinik für Gastroenterologie,
Hepatologie und Endokrinologie
Medizinische Hochschule Hannover
Carl-Neuberg-Str. 1
30625 Hannover
Germany
[email protected]
Dr. Marie-Louise Michel
Institut Pasteur
INSERM U845
Laboratoire de Pathogenèse des Virus de
l‘hépatite B
Département de Virologie
F-75015 Paris
France
[email protected]
Prof. Dr. Jacob Nattermann
Medizinische Klinik und Poliklinik I
Immunologisches Labor
Sigmund-Freud-Str. 25
53105 Bonn
Germany
[email protected]
Prof. Dr. Thomas Pietschmann
Experimentelle Virologie
TWINCORE Experimentelle und
Klinische Infektionsforschung
Feodor-Lynen-Straße 7
30625 Hannover
Germany
[email protected]
Alexander Ploss, Ph.D.
Assistant Professor of Molecular Biology
Department of Molecular Biology
Princeton University
Washington Road, LTL 110
Princeton, NJ 08544
USA
[email protected]
Prof. Dr. Ulrike Protzer
Virologie
Technische Universität München
Trogerstr. 30
81675 München
Germany
[email protected]
Barbara Rehermann, M.D.
Immunology Section
National Institute of Health
Building 10, Room 9B16
10 Center Drive
Bethesda, MD 20892-1800
USA
[email protected]
Prof. Dr. Roland M. Schmid
Innere Medizin II
Klinikum rechts der Isar
der Technischen Universität
Ismaninger Str. 22
81675 München
Germany
[email protected]
Prof. Dr. Robert Thimme
Innere Medizin II
Universitätsklinikum Freiburg
Hugstetter Str. 55
79106 Freiburg
Germany
[email protected]
13
PD Dr. Stephan Urban
Abteilung Molekulare Virologie
Im Neuenheimer Feld 350
69120 Heidelberg
Germany
[email protected]
Stefan Wieland, M.D.
Assistant Professor of
Experimental Virology
Scripps Research Institute
Dept. Immunology & Microbial Science
10550 North Torrey Pines Road
La Jolla, CA 92037
USA
[email protected]
14
Prof. Dr. Stefan Zeuzem
Innere Medizin I
Klinikum der Johann Wolfgang
Goethe-Universität Frankfurt
Theodor-Stern-Kai 7
60596 Frankfurt
Germany
[email protected]
Congress Office
During the Falk Workshop
Telephone: +49 (0)175/7795327
Klinikum rechts der Isar
Pavillon / Hörsaal B
Ismaninger Str. 22
81675 Munich
Germany
Opening Hours:
Thursday, January 29, 2015
Friday, January 30, 2015
10.00 – 18.30 h
8.00 – 12.30 h
Congress Fees
The participation in the Falk Workshop is free of charge, however registration is
mandatory.
Refreshments during coffee breaks and lunches on January 29 and 30, dinner on
January 29 and a copy of the abstract volume of the Falk Workshop are also free
of charge.
Admission to Scientific Events
For admission to scientific events your name badge should be clearly visible.
Hotel Accommodation
www.hotel.de
or www.hrs.com
Airport
Munich Airport: http://www.munich-airport.de
The 31th Annual Meeting of the German Association fort he
Study of the Liver will take place immediately following the Falk
Workshop (January 30 and 31, 2015).
15
Directions to University Hospital „Klinikum rechts der Isar“
From Munich Airport:
If you arrive at the Munich airport you can use a taxi or the train (S-Bahn) to get to
the Klinikum rechts der Isar.
A taxi will bring you to the Klinikum rechts der Isar in approximately 45-60 min and
costs around 70-90 €.
For the train (train costs around 10 €, duration about 50-60 min) follow the signs
S-Bahn at the main terminal of the airport to the train station. We recommend using
line S8 towards Munich (München) to station ‘Ostbahnhof’. Then change to underground line U5 or U4 (U-Bahn) in direction to ‘Max-Weber-Platz’ and get off at the
station ‘Max-Weber-Platz’. Follow the signs ‚Einsteinstraße‘ and ‚Einsteinstraße/Klinikum rechts der Isar‘.
B
From Central Train Station (Hauptbahnhof):
Follow the signs to the underground station and take line U4/Arabellapark or U5/
Neuperlach. Get off the train at ‘Max-Weber-Platz’ which is only four stations from
the central train station. Follow the signs ‚Einsteinstraße‘ and ‚Einsteinstraße/Klinikum
rechts der Isar‘.
P
Hörsaal B
Pavillion
16
17
General Information:
FALK FOUNDATION e.V.
Leinenweberstr. 5
79108 Freiburg
Germany
Congress Department
Telephone:+49(0)761/1514-0
Telefax:+49(0)761/1514-359
E-mail:[email protected]
www.falkfoundation.org